International twist to delegate projects this year

December 14, 2017

Project presentations had an extra twist this year with some delegates presenting via video from afar, explaining how they are changing services in their part of the country (or world in some cases). MasterClass graduates are changing the face of patient care. Through their projects, graduates have implemented changes that are making a valuable impact on service development […]

Continue Reading

Is everyone who could benefit from non-oral therapy receiving them? Know your 10%

December 12, 2017

by Sue Thomas The Non-Oral Therapy Roadshows have been a great success this year raising awareness of the potential treatments and non-oral pathways for people with Parkinson’s (PwP) who might have more complex therapy needs. Around 10% of each Parkinson’s population may require one of the non-oral therapies, namely apomorphine, deep brain stimulation or duodopa. […]

Continue Reading

MasterClass Moving On: Academy round up for 2017

December 12, 2017

by Dr Peter Fletcher As the 16th year of our Parkinson’s MasterClass(es) draws to a close it is time to take stock and reflect on 2017: more MasterClasses, more audits and two ‘Firsts’. Add to that NICE publishing new (well nearly new) guidelines, the World Parkinson’s Congress blog and the growing agenda around repurposing drugs and […]

Continue Reading

Reconsidering the “palliative phase” of Parkinson’s

December 12, 2017

by Dr Ed Richfield The model of Parkinson’s disease in four phases was first described by two founders of the original Parkinson’s MasterClass(1), and are well recognised by those familiar with the disease, particularly Academy alumni. This approach is useful in understanding the progressive nature of Parkinson’s disease (PD) and the implications this has for […]

Continue Reading

Non-oral therapy roadshows and the relevance of the NICE guidelines for Parkinson’s

December 12, 2017

by Dr Christopher Kobylecki Non-oral therapies for Parkinson’s disease comprise apomorphine infusion, deep brain stimulation (DBS) surgery, and levodopa-carbidopa intestinal gel (LCIG, Duodopa®). Whereas people with Parkinson’s disease typically respond consistently to oral medications for several years, motor fluctuations and levodopa-induced dyskinesia affect half of patients after 4-5 years (1). This heralds the “complex” phase […]

Continue Reading

James Parkinson memorial day: The man behind shaking palsy

October 23, 2017

James Parkinson FGS (11 April 1755 – 21 December 1824) was a surgeon, apothecary, geologist, palaeontologist, and political activist. He is most famous for his 1817 work, ‘An Essay on the Shaking Palsy’, in which he was the first to describe “paralysis agitans”, a condition that later became known as Parkinson’s disease.

Continue Reading

NICE Quality Standards advisory committee meeting for Parkinson’s

October 10, 2017

Public registration to observe the NICE Quality Standards committee meeting for Parkinson’s disease has opened on the NICE website. If you would like to register for this committee meeting, please do so via the following web page: https://www.nice.org.uk/event/qsac1-november-2017 Registration for this meeting will close on Thursday 19 October 2017.

Continue Reading